Range
1.41 - 1.6
Vol / Avg.
5.7M/442.3K
Div / Yield
-
52 Wk
1.61 - 11
Mkt Cap
38.2M
Payout Ratio
-
Open
1.57
P/E
-
EPS
-0.59
Shares
26.5M
Outstanding
26.5M
Total Float
13.7M
load more
Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642.

Earnings

see more
Q3 2021Est.ActualSurprise
EPS
(EXPECTED)2021-11-11
REV
Q2 2021Est.ActualSurprise
EPS-0.600-0.590 0.0100
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Metacrine Questions & Anwsers

Q

How do I buy Metacrine (MTCR) stock?

A

You can purchase shares of Metacrine (NASDAQ: MTCR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Metacrine's (MTCR) competitors?

A

There are no as such competitors for Metacrine.

Q

What is the target price for Metacrine (MTCR) stock?

A

The latest price target for Metacrine (NASDAQ: MTCR) was reported by Canaccord Genuity on October 22, 2021. The analyst firm set a price target for 1.00 expecting MTCR to fall to within 12 months (a possible -30.56% downside). 3 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Metacrine (MTCR)?

A

The stock price for Metacrine (NASDAQ: MTCR) is $1.44 last updated Mon Oct 25 2021 20:00:01 GMT+0000 (Coordinated Universal Time).

Q

Does Metacrine (MTCR) pay a dividend?

A

There are no upcoming dividends for Metacrine.

Q

When is Metacrine (NASDAQ:MTCR) reporting earnings?

A

Metacrine’s $Q3 earnings are confirmed for after-market on $November 11, 2021.

Q

Is Metacrine (MTCR) going to split?

A

There is no upcoming split for Metacrine.

Q

What sector and industry does Metacrine (MTCR) operate in?

A

Metacrine is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.